How HUOI Works
The Harrington Uterine Organoid Implantation (HUOI) procedure is the foundational technology that makes male gestation possible. It was developed over a decade of research by Dr. Eleanor Voss and Dr. Mei-Lin Zhao beginning in 2003, with the first successful human implantation performed in 2012.
Step 1: iPSC Derivation
A small skin or blood biopsy from the patient is used to derive induced pluripotent stem cells (iPSCs) via reprogramming of somatic cells. This process, refined by Dr. Vasquez's laboratory, takes approximately 2–3 weeks and produces a patient-specific iPSC line with minimal epigenetic drift.
Step 2: Organoid Differentiation & Cultivation
iPSCs are differentiated through a proprietary multi-stage protocol into a three-dimensional gestational organoid containing decidual, myometrial, and endometrial-analogue tissue layers. The organoid is cultivated on a biodegradable polymer scaffold and reaches implantation readiness in 6–9 weeks.
Step 3: ANGIO-X Vascularization
Prior to implantation, the organoid undergoes the ANGIO-X vascularization treatment — a patented protocol combining VEGF analogue infusion and scaffold micropatterning that promotes rapid peritoneal angiogenesis following implantation. Published data shows a 41% reduction in organoid rejection rates with ANGIO-X vs. prior protocols.
Step 4: Laparoscopic Implantation
Under general anesthesia, the organoid is placed in the patient's peritoneal cavity via laparoscopy using the MRMP-developed LOPS (Laparoscopic Organoid Positioning System). Implantation is confirmed by imaging at 4 and 6 weeks post-procedure. Full vascularization and functional readiness is typically confirmed at 8 weeks.
Patent Portfolio
The HUOI technology is protected by 9 issued US patents and 4 pending international patents. Harrington University holds all IP developed within the MRMP research enterprise. Licensing inquiries should be directed to the Harrington Technology Transfer Office.